Prognostic relevance of serum Beta2-microglobulin in acute myeloid leukemia

L. Melillo, N. Cascavilla, G. Lombardi, M. Carotenuto, P. Musto

Research output: Contribution to journalArticlepeer-review


Serum levels of β2-microglobulin (S-B2m) were analysed at diagnosis in 69 cases of acute myeloid leukemias (AML) as a possible prognostic indicator. S-B2m was correlated to various clinical and laboratory features and with respect to response to chemotherapy and following clinical outcome. SB2m was found to be increased >3mg/l) in 40.6% of tested patients and, in particular, in the monocytic variants (M4, M5) of AML (4.2 versus 2.3mg/l, p3mg/l and white blood cell count >20x109/l were independent variables significantly influencing disease-free survival in responsive patients (five years DFS for S-B2m > or

Original languageEnglish
Pages (from-to)1076-1078
Number of pages3
Issue number10
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Cancer Research
  • Hematology


Dive into the research topics of 'Prognostic relevance of serum Beta2-microglobulin in acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this